STAT3 and non-small cell lung carcinoma: The JAK2/STAT3 signaling pathway is frequently activated in NSCLC and regulates a variety of cell functions, including proliferation, cell differentiation, metastasis, angiogenesis, apoptosis, and immune response; hence, STAT3 and its upstream activator JAK1/2 are considered promising targets [50–52].